Vyne Historical Balance Sheet

VYNE Stock

USD 2.96 0.01 0.34%

Trend analysis of Vyne Therapeutics balance sheet accounts such as Total Assets of 82 M, Other Current Liab of 5.6 M, Total Current Liabilities of 10.9 M or Total Stockholder Equity of 93.2 M provides information on Vyne Therapeutics' total assets, liabilities, and equity, which is the actual value of Vyne Therapeutics to its prevalent stockholders. By breaking down trends over time using Vyne Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vyne Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vyne Therapeutics is a good buy for the upcoming year.

Vyne Therapeutics Inventory

105,972

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

About Vyne Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vyne Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Vyne Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vyne Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vyne currently owns. An asset can also be divided into two categories, current and non-current.

Vyne Therapeutics Balance Sheet Chart

At present, Vyne Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 3.3 M, whereas Other Current Liabilities is forecasted to decline to about 5.6 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Net Receivables

Add Fundamental

Total Assets

Total assets refers to the total amount of Vyne Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vyne Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Vyne Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vyne Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Vyne Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Vyne Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Vyne Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 3.3 M, whereas Other Current Liabilities is forecasted to decline to about 5.6 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	11.2M	7.0M	5.6M	5.6M
Total Assets	67.0M	40.8M	97.7M	82.0M

Other Current Liab Total Assets

Vyne Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.53	0.58	0.82	-0.02	-0.37	0.54	0.21	0.93	0.59	0.35	-0.52	0.38	0.38	-0.46	0.99	-0.23	0.68	-0.52	0.38	0.44	-0.74	0.3	0.34	0.14	0.64
Other Current Liab	0.53		0.9	0.56	0.06	-0.8	0.79	0.38	0.22	0.82	0.39	-0.63	0.79	0.77	-0.45	0.49	0.2	0.37	-0.64	0.73	0.81	-0.47	0.96	0.93	0.82	-0.24
Total Current Liabilities	0.58	0.9		0.55	0.29	-0.74	0.95	0.13	0.28	0.79	0.33	-0.5	0.81	0.73	-0.38	0.53	0.1	0.59	-0.8	0.76	0.75	-0.65	0.86	0.85	0.63	-0.14
Total Stockholder Equity	0.82	0.56	0.55		-0.23	-0.61	0.55	0.3	0.76	0.75	0.58	-0.89	0.46	0.65	-0.88	0.82	0.05	0.46	-0.62	0.28	0.68	-0.75	0.39	0.45	0.15	0.5
Net Debt	-0.02	0.06	0.29	-0.23		-0.15	0.19	-0.79	-0.15	0.06	0.11	0.31	0.24	0.13	0.36	-0.11	0.06	0.37	-0.32	0.24	0.12	-0.18	0.13	0.18	0.13	-0.05
Retained Earnings	-0.37	-0.8	-0.74	-0.61	-0.15		-0.65	-0.08	-0.14	-0.88	-0.79	0.75	-0.81	-0.99	0.63	-0.34	-0.39	-0.43	0.82	-0.44	-0.99	0.62	-0.84	-0.88	-0.6	0.11
Accounts Payable	0.54	0.79	0.95	0.55	0.19	-0.65		0.09	0.27	0.71	0.25	-0.49	0.76	0.64	-0.41	0.5	0.03	0.57	-0.73	0.59	0.64	-0.65	0.76	0.71	0.45	-0.1
Cash	0.21	0.38	0.13	0.3	-0.79	-0.08	0.09		0.17	0.17	-0.06	-0.36	-0.04	0.09	-0.31	0.27	-0.12	-0.28	0.09	0.36	0.13	0.15	0.31	0.26	0.42	-0.15
Cash And Short Term Investments	0.93	0.22	0.28	0.76	-0.15	-0.14	0.27	0.17		0.39	0.28	-0.42	0.15	0.17	-0.42	0.96	-0.27	0.61	-0.35	0.1	0.22	-0.67	-0.03	0.04	-0.17	0.83
Common Stock Total Equity	0.59	0.82	0.79	0.75	0.06	-0.88	0.71	0.17	0.39		0.56	-0.8	0.78	0.86	-0.72	0.57	0.35	0.47	-0.86	0.55	0.87	-0.75	0.77	0.84	0.51	-0.03
Common Stock Shares Outstanding	0.35	0.39	0.33	0.58	0.11	-0.79	0.25	-0.06	0.28	0.56		-0.62	0.4	0.82	-0.55	0.34	0.09	0.37	-0.58	0.06	0.82	-0.49	0.41	0.52	0.29	0.33
Non Current Liabilities Total	-0.52	-0.63	-0.5	-0.89	0.31	0.75	-0.49	-0.36	-0.42	-0.8	-0.62		-0.56	-0.78	0.96	-0.52	-0.34	-0.19	0.57	-0.23	-0.78	0.57	-0.55	-0.57	-0.31	-0.14
Other Current Assets	0.38	0.79	0.81	0.46	0.24	-0.81	0.76	-0.04	0.15	0.78	0.4	-0.56		0.77	-0.41	0.34	0.57	0.64	-0.77	0.39	0.78	-0.71	0.77	0.74	0.44	-0.18
Other Stockholder Equity	0.38	0.77	0.73	0.65	0.13	-0.99	0.64	0.09	0.17	0.86	0.82	-0.78	0.77		-0.68	0.35	0.35	0.42	-0.82	0.43	0.99	-0.62	0.81	0.86	0.58	-0.06
Total Liab	-0.46	-0.45	-0.38	-0.88	0.36	0.63	-0.41	-0.31	-0.42	-0.72	-0.55	0.96	-0.41	-0.68		-0.47	-0.3	-0.13	0.54	-0.14	-0.66	0.56	-0.37	-0.42	-0.12	-0.2
Total Current Assets	0.99	0.49	0.53	0.82	-0.11	-0.34	0.5	0.27	0.96	0.57	0.34	-0.52	0.34	0.35	-0.47		-0.23	0.66	-0.5	0.34	0.41	-0.73	0.25	0.3	0.09	0.66
Common Stock	-0.23	0.2	0.1	0.05	0.06	-0.39	0.03	-0.12	-0.27	0.35	0.09	-0.34	0.57	0.35	-0.3	-0.23		0.07	-0.33	0.0	0.33	-0.25	0.25	0.23	0.06	-0.37
Other Liab	0.68	0.37	0.59	0.46	0.37	-0.43	0.57	-0.28	0.61	0.47	0.37	-0.19	0.64	0.42	-0.13	0.66	0.07		-0.71	0.2	0.44	-0.87	0.26	0.29	-0.05	0.49
Net Tangible Assets	-0.52	-0.64	-0.8	-0.62	-0.32	0.82	-0.73	0.09	-0.35	-0.86	-0.58	0.57	-0.77	-0.82	0.54	-0.5	-0.33	-0.71		-0.54	-0.81	0.86	-0.64	-0.73	-0.33	-0.07
Property Plant And Equipment Net	0.38	0.73	0.76	0.28	0.24	-0.44	0.59	0.36	0.1	0.55	0.06	-0.23	0.39	0.43	-0.14	0.34	0.0	0.2	-0.54		0.46	-0.24	0.72	0.74	0.78	-0.32
Current Deferred Revenue	0.44	0.81	0.75	0.68	0.12	-0.99	0.64	0.13	0.22	0.87	0.82	-0.78	0.78	0.99	-0.66	0.41	0.33	0.44	-0.81	0.46		-0.63	0.83	0.87	0.61	-0.03
Non Current Assets Total	-0.74	-0.47	-0.65	-0.75	-0.18	0.62	-0.65	0.15	-0.67	-0.75	-0.49	0.57	-0.71	-0.62	0.56	-0.73	-0.25	-0.87	0.86	-0.24	-0.63		-0.35	-0.42	0.03	-0.45
Non Currrent Assets Other	0.3	0.96	0.86	0.39	0.13	-0.84	0.76	0.31	-0.03	0.77	0.41	-0.55	0.77	0.81	-0.37	0.25	0.25	0.26	-0.64	0.72	0.83	-0.35		0.97	0.88	-0.44
Other Assets	0.34	0.93	0.85	0.45	0.18	-0.88	0.71	0.26	0.04	0.84	0.52	-0.57	0.74	0.86	-0.42	0.3	0.23	0.29	-0.73	0.74	0.87	-0.42	0.97		0.87	-0.36
Net Receivables	0.14	0.82	0.63	0.15	0.13	-0.6	0.45	0.42	-0.17	0.51	0.29	-0.31	0.44	0.58	-0.12	0.09	0.06	-0.05	-0.33	0.78	0.61	0.03	0.88	0.87		-0.52
Short Term Investments	0.64	-0.24	-0.14	0.5	-0.05	0.11	-0.1	-0.15	0.83	-0.03	0.33	-0.14	-0.18	-0.06	-0.2	0.66	-0.37	0.49	-0.07	-0.32	-0.03	-0.45	-0.44	-0.36	-0.52

Click cells to compare fundamentals

Vyne Therapeutics Account Relationship Matchups

Vyne Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Other Current Liab	485K	15.2M	11.2M	7.0M	5.6M	5.6M
Total Current Liabilities	10.7M	21.5M	18.4M	9.3M	7.5M	10.9M
Total Stockholder Equity	68.5M	37.5M	48.6M	31.2M	88.7M	93.2M
Net Debt	(30.1M)	(22.8M)	(41.9M)	(31.3M)	(30.4M)	(31.9M)
Retained Earnings	(184.3M)	(566.2M)	(639.5M)	(662.7M)	(691.3M)	(656.8M)
Accounts Payable	3.8M	4.8M	6.5M	2.4M	1.7M	3.3M
Cash	30.8M	57.6M	42.3M	30.9M	30.6M	36.6M
Cash And Short Term Investments	136.3M	76.9M	58.6M	42.3M	93.3M	70.3M
Common Stock Shares Outstanding	471.4K	1.8M	2.9M	3.2M	10.3M	10.8M
Liabilities And Stockholders Equity	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Non Current Liabilities Total	34.3M	34.8M	6.9M	211K	1.4M	1.3M
Other Current Assets	1.4M	4.6M	6.1M	7.2M	2.7M	3.6M
Other Stockholder Equity	252.8M	603.7M	688.2M	692.3M	780.0M	819.0M
Total Liab	10.7M	56.2M	18.4M	9.6M	9.0M	8.5M
Total Current Assets	78.3M	87.3M	63.2M	38.3M	96.0M	78.4M
Other Liab	1.4M	1.1M	880K	769K	884.4K	997.5K
Net Tangible Assets	17.6M	37.5M	48.6M	31.2M	28.1M	48.6M
Property Plant And Equipment Net	769K	2.1M	354K	282K	207K	196.7K
Non Current Assets Total	842K	6.5M	3.9M	2.5M	1.7M	2.9M
Non Currrent Assets Other	73K	4.3M	3.5M	2.2M	1.5M	1.6M
Other Assets	744K	4.9M	3.5M	2.5M	2.9M	1.9M
Net Receivables	135K	15.8M	7.6M	5.2M	5.9M	5.3M
Short Term Investments	86.7M	46.2M	1.0M	0.0	62.6M	65.8M
Property Plant And Equipment Gross	98K	2.1M	354K	0.0	207K	412.2K
Accumulated Other Comprehensive Income	(51K)	(96K)	24K	26K	29.9K	31.4K
Non Current Liabilities Other	22K	7K	457K	1.3M	1.5M	1.6M
Property Plant Equipment	2.2M	4.6M	2.1M	354K	318.6K	302.7K
Net Invested Capital	68.5M	70.7M	48.6M	31.2M	88.7M	59.9M
Net Working Capital	67.7M	65.8M	44.8M	28.9M	88.4M	55.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:

How To Invest In Vyne

Details

Is Vyne Stock a good investment?

Details

What is Vyne Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.72

Revenue Per Share

0.016

Quarterly Revenue Growth

0.467

Return On Assets

(0.35)

Return On Equity

(0.60)

The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vyne Historical Balance Sheet

Vyne Therapeutics Inventory

105,972

About Vyne Balance Sheet Analysis

Vyne Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Vyne Therapeutics balance sheet Correlations

Vyne Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vyne Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Current Deferred Revenue	+ 0.99	Other Stockholder Equity
Other Assets	+ 0.97	Non Currrent Assets Other
Non Currrent Assets Other	+ 0.96	Other Current Liab
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total

Current Deferred Revenue	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.89	Total Stockholder Equity
Other Assets	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.88	Retained Earnings
Total Liab	- 0.88	Total Stockholder Equity